4D Molecular Therapeutics (FDMT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on 4D Molecular Therapeutics (FDMT) is Neutral.

The composite score behind that read is +0.03, weighing +0.67 of bullish evidence against -0.24 bearish.

4D Molecular Therapeutics last closed at $13.33, +4.96% on the session.

Against the IVW growth benchmark the position is +4.16% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

4D Molecular Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks 4D Molecular Therapeutics in the 20th percentile on return on equity, where 100 is best.

4D Molecular Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $701.60M.

StockMap tracks 4D Molecular Therapeutics as the 156th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite 4D Molecular Therapeutics ranks 75th of 381 in the group, against a group median of -0.08.